Targeting Cancer STEM cells, finally.

Dr. Weeks’ Comment:  Here below,  we begin to see efforts to target the lethal aspect of cancer, the cancer STEM cells. Note that chemo and radiation do NOT kill cancer STEM cells, only cancer TUMOR cells.  Note that “simultaneous targeting of EGFR and PDGFR” (which proves beneficial in the treatment of glioblastoma) require anti-inflammatory processes and we celebrate the new age of cancer care which jettisons chemo and radiation and embraces safe and effective anti-inflammatory agents such as seed based nutrients including black cumin seed, black raspberry seed and Chardonnay grape seed as well as well validated herbs such as curcumin and other anti-inflammatory foods.


TITLE:    PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment

Author: Carlo CenciarelliHany ES MareiManuela ZonfrilloPasquale PierimarchiEmanuela PaldinoPatrizia Casalbore Armando FelsaniAngelo Luigi VescoviGiulio MairaAnnunziato Mangiola

Source: Molecular Cancer 2014, 13:247


Cancer stem cells (CSC) represent a rare fraction of cancer cells characterized by resistance to chemotherapy and radiation, therefore nowadays there is great need to develop new targeted therapies for brain tumors and our study aim to target pivotal transmembrane receptors such as Notch, EGFR and PDGFR, which are already under investigation in clinical trials setting for the treatment of Glioblastoma Multiforme (GBM).

Methods: MTS assay was performed to evaluate cells response to pharmacological treatments. Quantitative RT-PCR and Western blots were performed to state the expression of Notch1, EGFR and PDGFRalpha/beta and the biological effects exerted by either single or combined targeted therapy in GBM CSC.

GBM CSC invasive ability was tested in vitro in absence or presence of Notch and/or EGFR signaling inhibitors. 

Results: In this study, we investigated gene expression and function of Notch1, EGFR and PDGFR to determine their role among GBM tumor core- (c-CSC) vs. peritumor tissue-derived cancer stem cells (p-CSC) of six cases of GBM.

Notch inhibition significantly impaired cell growth of c-CSC compared to p-CSC pools, with no effects observed in cell cycle distribution, apoptosis and cell invasion assays. Instead, anti-EGFR therapy induced cell cycle arrest, sometimes associated with apoptosis and reduction of cell invasiveness in GBM CSC.

In two cases, c-CSC pools were more sensitive to simultaneous anti-Notch and anti-EGFR treatment than either therapy alone compared to p-CSC, which were mostly resistant to treatment. We reported the overexpression of PDGFRalpha and its up-regulation following anti-EGFR therapy in GBM p-CSC compared to c-CSC.

RNA interference of PDGFRalpha significantly reduced cell proliferation rate of p-CSC, while its pharmacological inhibition with Crenolanib impaired survival of both CSC pools, whose effects in combination with EGFR inhibition were maximized. 

Conclusions: We have used different drugs combination to identify the more effective therapeutic targets for GBM CSC, particularly against GBM peritumor tissue-derived CSC, which are mostly resistant to treatments. Overall, our results provide the rationale for simultaneous targeting of EGFR and PDGFR, which would be beneficial in the treatment of GBM.


Leave a Comment

Your email address will not be published. Required fields are marked *